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AbstrAct
Objectives Recent investigations in humans and mouse 
models with lupus have revealed evidence of mitochondrial 
dysfunction and production of mitochondrial reactive 
oxygen species (mROS) in T cells and neutrophils. This can 
provoke numerous cellular changes including oxidation 
of nucleic acids, proteins, lipids and even induction of 
cell death. We have previously observed that in T cells 
from patients with lupus, the increased mROS is capable 
of provoking oligomerisation of mitochondrial antiviral 
stimulator (MAVS) and production of type I interferon 
(IFN- I). mROS in SLE neutrophils also promotes the 
formation of neutrophil extracellular traps (NETs), which 
are increased in lupus and implicated in renal damage. 
As a result, in addition to traditional immunosuppression, 
more comprehensive treatments for lupus may also include 
non- immune therapy, such as antioxidants.
Methods Lupus- prone MRL- lpr mice were treated from 
weaning for 11 weeks with the mitochondria- targeted 
antioxidant, MitoQ (200 µM) in drinking water. Mice 
were then assessed for ROS production in neutrophils, 
NET formation, MAVS oligomerisation, serum IFN- I, 
autoantibody production and renal function.
Results MitoQ- treated mice manifested reduced 
neutrophil ROS and NET formation, decreased MAVS 
oligomerisation and serum IFN- I, and reduced immune 
complex formation in kidneys, despite no change in serum 
autoantibody .
Conclusions These findings reveal the potential 
utility of targeting mROS in addition to traditional 
immunosuppressive therapy for lupus.
IntROduCtIOn
SLE is a complex and heterogeneous autoim-
mune syndrome characterised by numerous 
abnormalities, including various autoanti-
bodies, the appearance of unusual CD4- CD8- 
TCR-αβ+ cells, altered metabolism of lympho-
cytes, a type I interferon (IFN- I) gene signa-
ture in peripheral blood mononuclear cells 
(PBMC), increased formation of neutrophil 
extracellular traps (NETs), and deposition 
of immunoglobulins and complement at 
renal glomeruli.1–10 Each of these immune 
abnormalities may provoke different aspects 
of the disease, and each also may be driven 
by different environmental and genetic aber-
rations. Recent work has also revealed the 
importance of non- immune factors, such as 
oxidative stress, in the development of end- 
organ damage in SLE, shifting the paradigm 
of SLE pathogenesis from that of a disease 
provoked solely by a disturbed immune 
system.1 7 Thus, fully effectively treatment of 
SLE may require inhibiting pathways in addi-
tion to those targeted by traditional immuno-
suppressive medications.
Neutrophil activation in response to glomer-
ular immune complexes contributes to lupus 
glomerulonephritis, in part through the 
production of mitochondrial reactive oxygen 
species (mROS) that can directly injure tissue 
through oxidation of lipids, proteins, DNA 
and induction of apoptosis.11 12 We have shown 
previously that immune complex activation of 
neutrophils can also lead to the formation of 
NETs, which can release oxidised genomic 
and mitochondrial DNA and promote the 
production of IFN- I.10 12 Furthermore, a subset 
of low- density granulocytes from patients with 
SLE has an enhanced capacity to form NETs 
in an mROS- dependent manner, and these 
structures have been observed in the kidneys 
of patients with lupus nephritis as well as in 
other lupus- affected tissues.11 13
We have also previously observed that T 
lymphocytes from patients with SLE manifest 
mitochondrial dysfunction as evidenced by 
enlarged mitochondria and elevated mROS 
that can induce oxidative damage.14 The 
mROS triggers the spontaneous oligomeri-
sation of the mitochondrial antiviral stimu-
lator (MAVS) protein and downstream IFN- I 
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production.15 This was likely due in part to induction 
of cysteine disulfide bonding in the caspase recritment 
domain (CARD) of MAVS, since a C79F polymorphism of 
MAVS known to be associated with milder SLE16 did not 
efficiently oligomerise nor induce IFN- I with mROS.15 In 
addition, we observed that oligomerised MAVS is reversed 
in vitro in the presence of the mitochondrial antioxidant, 
MitoQ.15 Consequently, mROS and resulting oxidative 
damage emerge as possible driving forces in certain 
aspects of SLE, and hence represent a target for therapy.
The process that promotes the mitochondrial abnor-
malities in human SLE T cells is unknown. Hence, we 
examined whether a similar phenomenon of enlarged 
mitochondria and spontaneous MAVS oligomerisation 
might occur in any of the T- cell subsets of lupus- prone 
MRL- lpr mice. T cells in these mice accumulate in large 
numbers in lymphoid organs through dysregulated 
homeostatic proliferation that is enhanced in the absence 
of the death receptor, Fas (CD95).17 The dysregulation of 
T cells includes the emergence with age of an increasingly 
large proportion of polyclonal CD4–CD8– TCR-αβ+ cells 
that derive from CD8+ precursors during homeostatic 
proliferation.17 A CD4–CD8– TCR-αβ+ subset also occurs 
in human SLE.3 4 Similar to human SLE T cells, the lpr 
CD4–CD8– TCR-αβ+ subset also manifested enlarged mito-
chondria and spontaneous MAVS oligomerisation. We 
thus investigated further the ability of the mitochondria- 
targeted antioxidant MitoQ in vivo to reverse mROS and 
NET formation, MAVS oligomerisation, as well as to test 
its therapeutic potential on lupus disease manifestations 
in MRL- lpr mice.
MethOds
Mice
Mice were bred and housed in the Association for Assess-
ment and Accreditation of Laboratory Animal Care 
International- approved animal facilities of The Univer-
sity of Vermont Larner College of Medicine. Original 
breeding pairs of MRL/MpJ- Faslpr (MRL- lpr) mice were 
obtained from Jackson Laboratory (Bar Harbor, Maine, 
USA). All breeding and animal studies were conducted 
in accordance with the policies of The University of 
Vermont’s Animal Care and Use Committee.
MitoQ treatment
Mice were weaned at 4 weeks and placed on either 
drinking water alone or 200 µM MitoQ (MitoQ, Auck-
land, NZ) in drinking water. Bottles were changed weekly. 
After 11 weeks of treatment, mice were euthanised and 
kidneys harvested for histological analysis. Brachial and 
axillary lymph nodes were assessed for cell number and 
lymphocyte subsets were determined by flow cytometry. 
Neutrophils were purified from bone marrow as previ-
ously described.10 Serum was obtained for autoantibodies, 
creatinine and blood urea nitrogen (BUN). Urine was 
obtained for creatinine measurement.
Lymphocyte preparation
Single cell suspensions of lymph nodes were prepared in 
Roswell Park Memorial Institute (RPMI) 1640 (CellGro, 
Corning, Manassas, Virginia, USA) containing 25 mM 4-(2- 
hydroxyehtyl)-1- piperazineethanesulfonic acid (HEPES), 
5% v/v bovine calf serum (HyClone, Logan, Utah, USA), 
5×10−5 M β-mercaptoethanol (Sigma, St. Louis, Missouri, 
USA), 100 U/mL penicillin and 100 U/mL streptomycin 
(Life Technologies- Invitrogen; Grand Island, New York, 
USA) (RPMI/5% bovine calf serum (BCS)). CD8+ and 
CD4–CD8–TCRαβ+ T cells were isolated by negative selec-
tion. Lymph node cells were incubated with the appro-
priate antibodies (see below) for 30 min on ice. After 
washing, the cells were incubated by rocking with goat 
anti- rat and goat anti- mouse IgG- coated beads (Qiagen, 
Valencia, California, USA) for 45 min at 4°C. Antibody- 
coated cells were removed by magnetic depletion. To 
obtain CD8+ T cells, cell suspensions were incubated with 
anti- class II (3F12), anti- CD11b (M1/70), anti- NK1.1 
(PK136), anti- kappa (187.1), anti- CD4 (GK1.5) and anti- 
CD45R (B220, RA3GB2). To isolate CD4–CD8–TCRαβ+ T 
cells, cells were incubated with anti- class II (3F12), anti- 
CD11b (M1/70), anti- NK1.1 (PK136), anti- kappa (187.1), 
anti- CD4 (GK1.5) and anti- CD8 (Tib105).
Antibodies and flow cytometry
The following antibodies to murine cell surface proteins 
were purchased from BD Biosciences (San Jose, Cali-
fornia, USA): allophycocyanin (APC)- conjugated anti- 
TCRβ and Pacific Blue- conjugated anti- CD45R (B220). 
The following antibodies were purchased from Life 
Technologies- Invitrogen: phycoerythrin (PE)- conjugated 
anti- CD44, PE- Texas Red- conjugated anti- CD4, PE Cy5.5- 
conjugated anti- CD8 and Pacific Orange- conjugated 
anti- CD45. The following antibodies were purchased 
from BioLegend (San Diego, California, USA): Alexa 
647- conjugated anti- TCRγδ, Alexa 700- conjugated anti- 
CD19 and Pacific Blue- conjugated anti- CD19. Live Dead 
Fixable Blue was purchased from Life Technologies- 
Molecular Probes. Lyophilised rat IgG and hamster IgG 
(MP Biochemicals, Solon, Ohio, USA) were resuspended 
in phosphate- buffered saline (PBS) and stored at −80°C.
For direct staining, single cell suspensions were washed 
with cold (4°C) PBS and then incubated with Live Dead 
Fixable Blue Stain (Life Technologies- Molecular Probes, 
Eugene, Oregon, USA) in PBS for 30 min at 4°C. The cells 
were washed with cold PBS containing 1% w/v bovine 
serum albumin (BSA) fraction V (Sigma) (PBS/1% BSA) 
and then incubated with a mixture of rat IgG and hamster 
IgG (50 µg/mL each) for 30 min at 4°C. After washing, 
the cells were incubated with the appropriate antibodies 
in PBS/1% BSA, washed and fixed with freshly made 
1% v/v methanol- free formaldehyde (Ted Pella, Redding, 
California, USA) in PBS/1% BSA. Flow cytometry was 
performed on an LSR II (BD Biosciences) and the data 
were analysed using FloJo software (Tree Star, Ashland, 
Oregon, USA).
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Figure 1 MRL- lpr CD4–CD8– TCR-αβ+ cells have enlarged 
mitochondria and increased oxidative and glycolytic 
metabolism. (A) Lymph node cells from MRL- lpr mice were 
analysed by flow cytometry for the expression of TCR-αβ+, 
CD4, CD8 and mitochondrial mass using MitoTracker. (B) 
Electron micrographs (12 000×) of mitochondria from MRL- lpr 
CD8+ or CD4–CD8– T cells. Red bar inset represents 500 nm. 
(C) OCR and ECAR for freshly isolated MRL- lpr CD4+ plus 
CD8+ T cells or CD4–CD8– T cells determined in extracellular 
flux analyser. Shown are means±SEM of five replicates 
of each subset. (D) Spontaneous cell death following a 2- 
hour incubation in complete medium at 37°C. Findings and 
means±SEM for three experiments normalised to death rate 
of CD4+ plus CD8+ subset. Results are representative of three 
experiments. Statistical analysis was by unpaired t- test. DN, 
double negative; ECAR, extracellular acidification rate; OCR, 
oxygen consumption rate.
Analysis of mitochondrial morphology by transmission 
electron microscopy
Cells were fixed for 1 hour at 65°C in 2% paraformalde-
hyde and 2.5% glutaraldehyde (Polysciences, Warrington, 
Pennsylvania, USA) in 100 mM sodium cacodylate buffer 
(pH 7.2). Samples were washed in cacodylate buffer 
and then postfixed for 1 hour in 1% osmium tetroxide 
(Polysciences). Samples were then extensively rinsed in 
distilled H2O before undergoing en bloc staining for 
1 hour with 1% aqueous uranyl acetate (Ted Pella). After 
several rinses in distilled H2O, the samples were dehy-
drated in a graded series of ethanol and then embedded 
in Eponate 12 resin (Ted Pella). Sections (95 nm in thick-
ness) were cut with an Ultracut UC7 ultramicrotome 
(Leica Microsystems, Wetzlar, Germany), stained with 
uranyl acetate and lead citrate, and viewed on a JEOL 
1400 transmission electron microscope (JEOL USA) 
equipped with an XR611 high- resolution, 11- megapixel 
mid- mount charge- coupled device camera (Advanced 
Microscopy Techniques, Woburn, Massachusetts, USA).
semidenaturing detergent agarose gel electrophoresis (sdd-
AGe) for the detection of MAVs oligomers
SDD- AGE was performed according to a published 
protocol with minor modifications.18 Briefly, mitochon-
dria were resuspended in sample buffer (0.5× tris- borate 
EDTA (TBE), 10% glycerol, 2% sodium dodecyl sulfate 
(SDS) and 0.0025% bromophenol blue) and loaded 
onto a vertical 1.5% agarose gel. After electrophoresis 
in running buffer (1× TBE, 0.1% SDS) for 35 min with 
a constant voltage of 75 V at 4°C, proteins were trans-
ferred to polyvinylidene difluoride (PVDF) membranes 
with a Trans- Blot Turbo Transfer System in preparation 
for western blot analysis. PVDF membranes were blocked 
in Tris- buffered saline and 5% non- fat powdered milk 
and analysed with MAVS- specific antibody (Santa Cruz 
Biotechnology, Dallas, Texas, USA). Immunoreactive 
proteins were visualised with horseradish peroxidase–
labelled conjugates (Jackson ImmunoResearch, West 
Grove, Pennsylvania, USA) and developed with Clarity 
Western ECL Substrate (Bio- Rad, Hercules, California, 
USA). Chemiluminescence was detected and recorded 
with a Bio- Rad Chemidoc instrument. Densitometric 
measurements were performed in Image Lab image 
acquisition and analysis software (Bio- Rad).
Metabolism analysis
Real- time analysis of extracellular acidification rates and 
oxygen consumption rates were measured with the XFe96 
extracellular flux analyser (Agilent Technologies, Santa 
Clara, California, USA) according to the manufacturer’s 
specifications. Metabolic profiles were measured under 
basal conditions in non- buffered Dulbecco's Modified 
Eagle Medium (Sigma) containing 25 mM glucose, 2 mM 
L- glutamine and 1 mM sodium pyruvate, in response to 
1 mM oligomycin, 0.5 mM trifluoromethoxy carbonylcya-
nide phenylhydrazone (FCCP) and 1 mM rotenone/1 mM 
antimycin. Analysis was performed with the Wave Soft-
ware V.2.4 or V.2.6 (Agilent Technologies).
Quantification of nets and mROs in bone marrow neutrophils
The isolation of bone marrow- derived neutrophils and 
quantification of NETs and mROS were performed as 
previously described.10 Briefly, hindlimb marrow neutro-
phils were purified by Percoll gradient. Cells were seeded 
in a 96- well plate (2 00 000 cells/100 µL/well) in tripli-
cates for each dye and allowed to form NETs in the pres-
ence of SYTOX (externalised DNA, 1 µM final concen-
tration), Quant- It Picogreen (total DNA stock solution 
diluted 1:250) and MitoSox (200 ng/mL) (all from 
Thermo Fisher, Waltham, Massachusetts, USA). Fluores-
cence was measured at different time points for each dye, 
at the earliest time point 485/520 (Picogreen), 1 hour 
510/580 (MitoSox) and 2 hour 486/520 (SYTOX), using 
a FLUOstar Omega BMG Labtech (Cary, North Caroline, 
USA) plate reader. Picogreen measurement was used as 
the initial number of cells or total DNA.
Autoantibody quantification
Serum concentrations of autoantibodies were deter-
mined using commercially available ELISA kits (Alpha 
Diagnostic International, Texas, USA). Serum was diluted 
(1:125) in non- specific binding (NSB) buffer and the 
assay done following manufacturer’s instructions.
Assessment of kidney histology and function
Renal immune complex deposition was quantified as 
previously described10 using an Alexa Fluor 594 F(ab’)2- 
goat antimouse IgG (Thermo Fisher) and fluorescein 
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Figure 2 MRL- lpr CD4–CD8– TCR-αβ+ cells manifest 
spontaneously oligomerised mitochondrial antiviral stimulator 
(MAVS) and increased expression of type I interferon (IFN- 
I)- stimulated genes (ISG) and serum IFN- I. (A) Lymph node 
cells from MRL- lpr mice were separated into CD4–CD8– TCR-
αβ+ (double- negative (DN)) and CD4+ plus CD8+ (B220−) 
subsets and cell lysates prepared. Comparisons were made 
with lymph node cells from MRL+/+ wild- type (WT) or MAVS- 
knockout (KO) mice. Lysates were subjected to 1% agarose 
gels (upper panel) to selectively visualise MAVS oligomers, 
or SDS- PAGE (sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis; lower panel) to visualise total MAVS 
monomer levels. (B) Fold increase in RNA expression 
for several ISG comparing female MRL- lpr DN to naive 
CD8+CD44low cells of the same mice. RNA was hybridised to 
Affymetrix GeneChip Mouse 430 2.0. Results are from five 
untreated 10- week- old mice per experiment and performed 
three times. (C) Serum levels of IFN- I in female MRL+/+ WT 
and MRL- lpr mice. Shown are the mean±SEM of five mice of 
each type. Statistical analysis was by unpaired t- test. Results 
were very similar in three experiments. F, female; M, male.
Figure 3 In vivo MitoQ treatment reduces levels of reactive 
oxygen species (ROS) and neutrophil extracellular trap (NET) 
formation in neutrophils. Mice (eight mice per treatment 
group) were administered either drinking water alone, or 
water containing MitoQ (200 µM) for 11 weeks following 
weaning. Neutrophils were purified from bone marrow and 
assayed for (A) ROS production and (B) NET formation either 
spontaneously or following activation with A23187. Per cent 
control refers to the comparison of each value to the mean of 
female neutrophils with A23187 activation. Shown are points 
for individual mice and their mean for three experiments. 
Statistical analysis was unpaired t- test. ns, non- significant.
isothiocyanate (FITC)- antimurine C3 antibody (Immu-
nology Consultants Laboratories, Portland, Oregon USA). 
Nuclei were stained with Hoechst (1:500; Life Technolo-
gies, Carlsbad, California, USA). For quantification, three 
random images were obtained from each stained frozen 
section. The images were analysed with Image J software 
selecting the glomerular compartment to quantify mean 
pixels for each fluorescence channel used.
To quantify serum creatinine and eliminate the influ-
ence of chromogens in mouse serum that interfere with 
the classic Jaffe method for creatinine detection, an high 
performance liquid chromatography assay was used as 
previously described.19 Briefly, 5 µL serum were treated 
with 0.5 mL acetonitrile, centrifuged at 4°C at 13 000×g 
for 20 min, and supernatants were dried by SpeedVac and 
resuspended in mobile phase (5 mM sodium acetate, pH 
5.1). Duplicates were run on a 100×4.1 mm PRP- X200 
column (Hamilton, Reno, Nevada, USA) and isocrati-
cally eluted at 2 mL/min in an Agilent 1100 System, with 
ultraviolet detection at 234 nm. Absolute quantitation was 
determined with a standard curve of 2–50 ng creatinine 
(r2=0.999).
statistical analysis
Statistical analyses were performed using the graphing 
software Prism V.7 (GraphPad Software, La Jolla, Cali-
fornia, USA). The following statistical tests were used: 
paired and unpaired t- test when comparing two condi-
tions, one- way analysis of variance (ANOVA) with Tukey’s 
test for correction for multiple comparisons when 
comparing multiple conditions and two- way ANOVA with 
Sidak test for correction for multiple comparisons when 
comparing multiple variables across multiple conditions. 
All data met the assumptions of the statistical tests used 
and variation among the compared groups was similar.
ResuLts
MRL-lpr Cd4–Cd8– tCR-αβ+ cells have enlarged mitochondria, 
increased oxygen consumption and glycolysis
Our previous observations in human SLE T cells revealed 
that they manifest enlarged mitochondria, mROS 
production and spontaneous MAVS oligomerisation.5 14 15 
We thus examined lupus- prone MRL- lpr mouse T cells 
for similar features. Initial analysis revealed that lpr CD8+ 
T cells, the precursors of the CD4–CD8– TCR-αβ+ T 
cells,17 20 21 contained relatively low mitochondrial mass, 
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Figure 4 Reduced oxygen consumption and glycolysis following in vivo MitoQ treatment. Extracellular flux analysis for (A) 
oxygen consumption rate (OCR) and (B) glycolysis as measured by extracellular acidification rate (ECAR) for neutrophils from 
mice (six mice per group, two experiments) administered water alone or MitoQ (200 µM) in drinking water. Shown are mean and 
statistical analysis by unpaired t- test. Results are representative of three experiments.
Figure 5 Reduced mitochondrial antiviral stimulator (MAVS) 
oligomerisation and serum interferon (IFN)-β with MitoQ. 
(A) MAVS oligomers were assessed by western blot from 
non- denaturing agarose gels as described in the Materials 
and methods section. Shown are results from five mice 
per treatment group. Graphs indicate density of MAVS 
oligomers. (B) Serum IFNα as measured by ELISA. Shown are 
mean±SEM and statistical analysis by unpaired t- test. Results 
are representative of two experiments.
using MitoTracker and flow cytometry, whereas the CD4–
CD8– TCR-αβ+ T cells had markedly higher mitochon-
drial mass relative to the CD8+ T cells (figure 1A). Further 
analysis by electron microscopy revealed that, similar 
to human SLE T cells5 14 the lpr CD4–CD8– TCR-αβ+ T 
cells contained very large and rounded mitochondria, in 
contrast to the more typical elongated mitochondria of 
the CD8+ subset (figure 1B). This paralleled greater rates 
of oxygen consumption and glycolysis in the CD4–CD8– 
TCR-αβ+ subset, as detected by Seahorse extracellular 
flux analysis (figure 1C). The increased aerobic glycol-
ysis of CD4–CD8– TCR-αβ+ T cells is consistent with the 
known rapid proliferation by this subset in vivo.22 This 
is paralleled by increased spontaneous cell death of the 
CD4–CD8– TCR-αβ+ T cells compared with the CD4+ and 
CD8+ T cell subsets (figure 1D), consistent with previous 
observations that high levels of glycolysis in T cells, 
including CD4–CD8– TCR-αβ+ T cells, drives high levels of 
active caspase-3, rendering them prone to cell death.23 24 
Such increased cell death could contribute to the inflam-
matory response in these mice.
Given these parallels between T cells from human SLE 
and the CD4–CD8– TCR-αβ+ T cells of MRL- lpr mice, we 
examined whether they also manifested evidence of spon-
taneous MAVS oligomerisation and activation of IFN- I 
genes. Indeed, the CD4–CD8– TCR-αβ+ (B220+) subset 
contained MAVS oligomers, which were diminished in 
the CD4+ and CD8+ (B220−) fraction and non- existent in 
wild- type mice (figure 2A). This paralleled the upregula-
tion of several IFN- I- stimulated genes in the CD4–CD8– 
TCR-αβ+ T cells compared with the CD8+ precursors 
(figure 2B). Consistent with these findings, MRL- lpr mice 
had higher levels of serum IFNα compared with wild- type 
mice (figure 2C). Collectively, these findings suggest that 
mROS may drive MAVS oligomerisation in lpr CD4–CD8– 
TCR-αβ+ T cells as it does in human SLE. We thus consid-
ered that mROS and possible oxidative damage might 
also drive some of the disease manifestations in MRL- 
lpr mice, and elected to treat the mice in vivo with the 
mitochondria- targeted antioxidant MitoQ.
In vivo MitoQ treatment of MRL-lpr mice reduces ROs 
production and net formation by neutrophils
Increased production of mROS and NET formation has 
been observed in neutrophils of patients with SLE.10 11 As 
NET formation in human lupus is, at least in part, driven 
by mROS production, we initially examined whether the 
mitochondria- targeted antioxidant, MitoQ, would reduce 
neutrophil mROS and NET formation. MitoQ contains 
an antioxidant, ubiquinonol, coupled to a triphenylphos-
phonium moiety containing three phenyl groups to 
promote membrane permeabilisation, combined with a 
central positively charged phosphorous that draws the 
compound toward negative charges. As mitochondria are 
about 150–170 mV negative compared with the cytosol, 
which is itself a further 30–60 mV negative compared 
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Figure 6 MitoQ does not alter autoantibody titres in 
MRL- lpr mice. MRL- lpr mice received water only or water 
containing MitoQ for 11 weeks. Serum autoantibody titres 
were measured by ELISA. Results shown are the combined 
findings of three experiments normalised to the water- only 
controls. Numbers of MRL- lpr mice in each treatment group 
(n=H20/MitoQ) were: males ANA (n=13/14), males beta-2 
glycoprotein 1 (n=9/9), males cardiolipin (n=10/9), females 
ANA (n=18/22), females beta-2 glycoprotein 1 (n=10/13), and 
females cardiolipin (n=10/13).
Figure 7 MitoQ reduces kidney immune complexes in 
female mice. Kidneys were stained for C3 (green), IgG 
(red) and nuclei by Hoechst stain (blue) and imaged by 
fluorescence microscopy. The glomerular- associated 
fluorescence was analysed by pixel quantification in each 
fluorescence channel using Image J. An example is shown in 
(A) and summaries all mice analysed is shown in (B).
with the extracellular environment, Mito compounds are 
concentrated 500–1000× in mitochondria.25–27
Mice were administered MitoQ (200 µM) in their 
drinking water beginning at 4 weeks of age and continued 
for 11 weeks. No adverse effects of MitoQ (eg, weight, 
development) were observed in mice at this dose, consis-
tent with other studies.27–30 mROS production in neutro-
phils was initially examined by MitoSox fluorescence plate 
assay. This revealed a reduction in mROS production in 
MitoQ- treated mice, both spontaneously and following 
mROS stimulation with the calcium ionophore, A23187 
(figure 3A). These findings were observed for both male 
and female MRL- lpr mice. Consistent with these findings, 
NET formation was also reduced with MitoQ treatment. 
In male mice, this was statistically significant for sponta-
neous NET formation, and in females this was the case 
following A23187 stimulation (figure 3B).
Further analysis of metabolism in the neutrophils 
revealed reduced oxygen consumption with MitoQ, both 
at basal levels and following stimulation of respiration 
with the mitochondrial uncoupler FCCP (respiratory 
capacity) (figure 4A). In contrast, glycolysis was largely 
unchanged, except in the case of female mice where 
the glycolytic capacity, following addition of ATP synthe-
tase inhibitor oligomycin, was decreased with MitoQ 
(figure 4B). These results indicate that oral MitoQ modu-
lates lupus neutrophil immunometabolism and reduces 
their ability to form NETs.
MitoQ in vivo reduces MAVs oligomerisation and serum IFn-I
CD4–CD8– TCR-αβ+ T cells purified from MitoQ- treated 
mice revealed reduced levels of MAVS oligomerisation 
compared with mice receiving water only (figure 5A). This 
was paralleled by a reduction in serum IFNα (figure 5B). 
In contrast to the reduction of NET formation and MAVS 
oligomerisation, MitoQ treatment did not affect lymph 
node total cell numbers, the distribution of T- cell subsets, 
including CD4–CD8– TCR-αβ+ T cells, or B cells (not 
shown), nor the titres of serum autoantibodies (figure 6) 
in male or female MRL- lpr mice. This was somewhat antic-
ipated as MitoQ was not expected to alter events believed 
to be upstream of mROS production.
Reduced renal injury with MitoQ
MRL- lpr mice develop immune complex- mediated kidney 
damage with age.31 32 MitoQ treatment of female mice 
caused a reduction of the glomerular deposition of both 
C3 and IgG (figure 7). This was less apparent in male 
mice, but male control mice had less C3 and IgG depo-
sition than female control mice, so there was a narrower 
window in male mice in which to observe a difference 
with MitoQ. These findings were paralleled by increased 
urine excretion of creatinine, although without a change 
in urine albumin (figure 8A) and was also accompanied 
by a reduction in serum BUN and creatinine in female 
mice (figure 8B).
dIsCussIOn
The current findings suggest that inhibiting mROS and 
oxidative stress can mitigate certain aspects of autoim-
mune disease and organ damage in lupus- prone MRL- lpr 
mice. It has been appreciated for some time that T cells 
and neutrophils in patients with SLE manifest increased 
levels of ROS,5 6 but the consequences of this on other 
molecular abnormalities, immune dysregulation or 
disease manifestations remain largely unexplored. The 
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Figure 8 MitoQ improves renal function in female mice. Urine and serum were collected from mice at the end of 11 weeks 
on water alone or water containing MitoQ. (A) Urine creatinine and albumin concentrations were measured as detailed in the 
Material and methods section. (B) Serum blood urea nitrogen (BUN) and creatinine concentrations were determined as in the 
Materials and methods section. Results show mean and individual values for 8–10 mice in each treatment group and of each 
sex. Statistical analysis was unpaired t- test. Results are representative of two experiments.
current findings reveal that the mitochondria- targeted 
antioxidant MitoQ can reduce oligomerisation of MAVS 
and serum IFN- I, mitigate glomerular immune complex 
formation and help preserve renal function.
The IFN- I gene signature in PBMC is one of the hall-
marks of SLE,8 9 yet the mechanism is unclear. The IFN- I 
signature may be driven in part through engulfment of 
dead cells by macrophages and dendritic cells.33 The 
increased rate of cell death of neutrophils in patients 
with SLE, as well as the increased cell death of CD4–
CD8– TCR-αβ+ T cells in MRL- lpr mice and human SLE 
T cells, may both contribute to the source of dead cells. 
The released nucleic acids can trigger both ROS and 
IFN- I production. This is clear from genetic deficiencies 
in DNA clearance (eg, three prime repair exonuclease 
(TREX)) which lead to interferonopathies.34 35
Another source of ROS in human SLE comes from T 
cells, some of which manifest enlarged mitochondria.5 14 
We have shown previously that ROS can induce MAVS 
oligomerisation and IFN- I production in different cell 
types.15 We now observe that, similar to human SLE, mito-
chondrial enlargement and spontaneous MAVS oligom-
erisation arises in the MRL- lpr CD4–CD8– TCR-αβ+ subset. 
This has been attributed to an imbalance of mitochondrial 
biogenesis36 and turnover by mitophagy.37 Specifically, 
our previous studies of SLE T cells have demonstrated 
human retrovirus endogenous sequence (HRES)-1/ras- 
related protein 4 (RAB4)- mediated depletion of dynamin 
related protein 1 (Drp1), a mediator of mitochondrial 
fission.36 The accumulation of mitochondria in lupus T 
cells is sensitive to mTOR blockade, with clinical benefit 
in patients38 and mice39 with SLE.
The CD4–CD8– TCR-αβ+ subset, which also occurs in 
human SLE, including inflamed kidneys,40 arises from 
recurrent homeostatic proliferation of CD8+ precursor 
T cells.17 41 CD4–CD8– TCR-αβ+ T cells also derive from 
antigen- specific CD8+ T cells in wild- type mice only 
when the antigen is presented as a self- antigen.42 Gene 
expression profiling of these wild- type derived CD4–CD8– 
TCR-αβ+ T cells has revealed upregulation of genes for 
programmed cell death 1 (PD-1), interleukin 17, IFNγ, 
C- X- C Motif Chemokine Ligand 2 (CXCL2) and down-
regulation of CD127,43 exactly the same pattern observed 
in lpr CD4–CD8– TCR-αβ+ T cells.22 Thus, these unusual 
T cells are not unique to Fas- deficient lpr mice. These 
findings, in addition to our previous observations that 
T- cell homeostatic proliferation also leads to the upregu-
lation of genes involved with cytolysis and inflammation22 
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adds further importance why it is critical to regulate the 
homeostatic expansion of T cells with Fas. In addition to 
these gene expression changes, our findings also suggest 
that part of the programme of dysregulated T- cell homeo-
static proliferation in lpr mice includes mitochondrial 
enlargement leading to mROS production and MAVS 
oligomerisation.
MitoQ has shown therapeutic potential in a variety 
of conditions in which mROS has been implicated. 
These include animal models of Alzheimer’s disease,29 
liver fibrosis,30 NLR Family Pyrin Domain Containing 
3 (NLRP3) inflammasome- mediated colitis,28 cardiac 
ischaemia–reperfusion44 and the metabolic syndrome 
in Apolipoprotein E (ApoE)-/- mice.27 In human trials, 
MitoQ prevented inflammatory damage in a phase II study 
in hepatitis C,45 showed no benefit in Parkinson’s disease 
but was well tolerated46 and improved vascular function 
in older adults.47 Oxidative stress could be functioning at 
several levels in SLE, including induction of MAVS oligo-
merisation15 and oxidised mitochondrial DNA release 
during NET formation,10 each contributing to the activa-
tion of the IFN- I pathway. In addition, immune complex 
and complement deposition in renal glomeruli induces 
oxidative stress in renal epithelium.10 Thus, MitoQ may 
function at several points in reducing oxidative damage 
in the pathogenesis of SLE.
From our current understanding that MitoQ reduces 
mROS and oxidative stress and hence events downstream 
of mROS generation, we would not have anticipated 
MitoQ to affect events upstream of mROS production. 
These might include the development of lymphade-
nopathy of MRL- lpr mice, the generation of CD4–CD8– 
TCR-αβ+ T cells and the production of autoantibodies, 
which may result from the absence of cell death occur-
ring during homeostatic proliferation of lymphocytes.17 48 
Consequently, the upregulation of genes during T- cell 
homeostatic proliferation involved with cytolysis and 
inflammation, such as granzyme B, perforin and Fas- 
ligand,22 is likely to still contribute to inflammation during 
MitoQ therapy. Thus, fully effective therapy for SLE may 
require a combination of traditional immunosuppression 
with non- immune antioxidant therapy.
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